Page 194 - Drug Class Review
P. 194

Page 127 of 205
             Drug Effectiveness Review Project





                                        placebo   NR   NR   NR      23.29   54.1



















                                        rivastigmine 6-12 mg/d   NR   NR   NR      23.57   55.22  Timing of assessments: Primary outcome measures at baseline and weeks 12, 18 and 26; secondary  Scores on PDS improved in patients taking high dose RIV when compared with placebo, P < 0.05  (LOCF analysis); no significant difference observed between low dose RIV and placebo, P >  PDS scores significantly more improved for high dose RIV compared to placebo (P < 0.05) but  Scores on ADAS-Cog improved in patients taking high dose RIV (6-12 mg/d) when compared  with placebo, P < 0.05 (LOCF analysis); no significant difference  obser






                                    Alzheimer classification: Mild to moderately severe











                                 Groups similar at baseline: Yes



                                        rivastigmine 1-4 mg/d   NR   NR   NR      23.87   53.8  Primary Outcome Measures:  ADAS-Cog; PDS; CIBIC  Secondary Outcome Measures: MMSE; GDS   outcome measures at baseline and week 26   Health Outcome Measures:   0.05*    not for low dose RIV   Intermediate Outcome Measures:   RIV (1-4 mg/d) and placebo, P > 0.05*   not for low dose RIV

















                                                                                            •         •            •         •     •














             Final Report Update 1     Authors: Rösler et al.   Year: 1999   POPULATION  CHARACTERISTICS:       Mean age (years):   Sex (% female):   Ethnicity:   Other germane population qualities:   Baseline ADAS-Cog   •   Baseline PDS    •     OUTCOME ASSESSMENT:          RESULTS:     Alzheimer's Drugs
   189   190   191   192   193   194   195   196   197   198   199